NEW YORK (GenomeWeb) – Inflammatix, a startup spawned from a Stanford University research lab, seeks to measure gene expression patterns of a patient's immune response as a way to diagnose infectious disease.

In particular, Inflammatix anticipates that its first product will be a sepsis diagnostic — an 18-gene panel that will be able to tell from a blood sample whether a hospitalized patient has a bacterial, viral, or no infection so that physicians will be able to administer more appropriate treatments earlier.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.